Related Experiment Video
Updated: Jun 21, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Extensively drug-resistant tuberculosis: a new face to an old pathogen
Sheela Shenoi1, Gerald Friedland
1Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510-8002, USA. sheela.shenoi@yale.edu
Drug-resistant tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, is a growing global concern. This article reviews the current status, development, management, and control strategies for drug-resistant tuberculosis.
Area of Science:
- Public Health
- Infectious Diseases
- Microbiology
Background:
- Drug resistance in tuberculosis treatment has been historically underestimated.
- Recent emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis has increased global concern.
- Clinicians and public health bodies are increasingly focused on resistant tuberculosis strains.
Purpose of the Study:
- To outline the current global epidemiology of drug-resistant tuberculosis.
- To examine the mechanisms of drug resistance development in Mycobacterium tuberculosis.
- To discuss current therapeutic approaches and future control strategies for resistant tuberculosis.
Main Methods:
- Review of global surveillance data on drug-resistant tuberculosis.
- Analysis of scientific literature on tuberculosis drug resistance mechanisms.
- Synthesis of information on current treatment regimens and public health interventions.
Main Results:
- Widespread prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis globally.
- Understanding of key pathways and factors contributing to the development of drug resistance.
- Identification of challenges and successes in managing and controlling drug-resistant tuberculosis.
Conclusions:
- Drug-resistant tuberculosis poses a significant and escalating global health threat.
- Effective management requires updated treatment strategies and robust public health programs.
- Continued research and international collaboration are crucial for controlling the spread of resistant tuberculosis.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...